Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment Strategy for Low-grade Gliomas

This study has been terminated.
(Difficulty in recruiting patients)
Information provided by:
Sun Yat-sen University Identifier:
First received: May 8, 2009
Last updated: August 4, 2014
Last verified: May 2009

Although the prognosis of patients with low-grade glioma (LGG) is generally good, recurrence seems unavoidable in some patients because of the infiltrative growth of the tumors. How to treat LGGs is still under controversy. The role of radiation therapy and chemotherapy in the treatment of LGG need to be further investigated. The purpose of this study is the following:

  1. to investigate the role of early radiation therapy in MRI-determined total resected LGGs;
  2. to compare the efficacy of early radiation therapy and that of initial chemotherapy in the LGGs without total resection.

Condition Intervention Phase
Radiation: Radiation therapy
Drug: Temozolomide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment Strategy for Low-grade Gliomas

Resource links provided by NLM:

Further study details as provided by Sun Yat-sen University:

Primary Outcome Measures:
  • Efficacy of early radiation therapy in MRI-determined total resected LGGs: evaluated as 5-year progression-free survival. [ Time Frame: 10 years ]
  • Efficacy of early radiation therapy vs. initial chemotherapy with temozolomide in LGGs without total resection: evaluated as 5-year progression-free survival. [ Time Frame: 10 years ]

Estimated Enrollment: 500
Study Start Date: December 2007
Arms Assigned Interventions
Experimental: Total resection with early radiation
Total resected LGGs treated with early radiation
Radiation: Radiation therapy
No Intervention: Total resection without radiation
Total resected LGGs treated without radiation
Experimental: Residual LGGs with radiation
Residual LGGs treated with early radiation
Radiation: Radiation therapy
Experimental: Residual LGGs with chemo
Residual LGGS treated with temozolomide
Drug: Temozolomide


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed newly diagnosed low-grade gliomas
  • Karnofsky performance status of 60 or more

Exclusion Criteria:

  • Previous history of radiation therapy or chemotherapy for gliomas
  • Pregnant or breast feeding
  • Diagnosis of another malignancy may exclude subject from study
  • Evidence or history of bleeding diathesis
  • Evidence or history of hypersensitivity to temozolomide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00897377

China, Guangdong
Sun Yat-sen University
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Sun Yat-sen University
Study Chair: Zhongping Chen, M.D., Ph.D. Sun Yat-sen University
  More Information

Responsible Party: Zhongping CHEN, Department of Neurosurgery, Sun Yat-sen University Cancer Center Identifier: NCT00897377     History of Changes
Other Study ID Numbers: YP2008009
Study First Received: May 8, 2009
Last Updated: August 4, 2014

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on April 26, 2017